Showing posts with label cell therapy portfolio. Show all posts
Showing posts with label cell therapy portfolio. Show all posts
Monday, November 19, 2012
Updated cell therapy index portfolio
UPDATED AGAIN DECEMBER 1, 2012 BY ADDING NASDAQ:NWBO
This an update of a post originally released October 18. What has changed is we've added four companies (shown below in red).
...
There are certainly analysts, traders, and brokers who cover the public segment of the cell therapy industry with much more expertise and experience than I -- among them is Henry W. McCusker of Scimitar Equity (@henryw09 on Twitter).
As part of our tracking of the sector's financial data and trends, we have created a portfolio of public cell therapy companies comprised of the 34 companies listed below (linked to their page on Google Finance).
I've been watching this portfolio since the beginning of the calendar year (January 2012) and have been commenting on its performance as against some of the major indices. (Oct 8 post and Aug 10 post).
In addition to these occasional reports I will occasionally report on Twitter (@celltherapyblog) on the stocks in this portfolio which are enjoying the largest gains/losses and which have the largest/smallest trading volumes. From time-to-time I will aggregate this content into a blog post.
Symbol Name
ASTM Aastrom Biosciences, Inc.
ACTC Advanced Cell Technology, Inc.
ABH Angel Biotechnology Holdings Plc
ATHX Athersys, Inc.
AVMXY Avita Medical Ltd
BHRT Bioheart, Inc.
BLFS BioLife Solutions, Inc.
BTX BioTime, Inc.
CBAI Cord Blood America Inc.
CNDO Coronado Biosciences Inc.**
CCEL CRYO-CELL International, Inc.
CMXI Cytomedix, Inc.
CYTX Cytori Therapeutics Inc. (USA)
DNDN Dendreon Corporation
FCSC Fibrocell Science Inc
IMUC ImmunoCellular Therapeutics Ltd
ISCO International Stem Cell Corp
ISLT Islet Sciences Inc
LVCLY Living Cell Technologies **
MEDS Medistem Inc.
MSB Mesoblast limited
MLM Molecular Medicine SpA **
NBS Neostem Inc.
CUR Neuralstem, Inc.
NLNK NewLink Genetics Corp
NWBO Northwest Biotherapeutics, Inc.
OPXA Opexa Therapeutics Inc.
OSIR Osiris Therapeutics, Inc.
PSTI Pluristem Therapeutics Inc.
RENE ReNeuron Group Plc
REPCF RepliCel Life Sciences Inc. **
STEM StemCells, Inc.
TNGN Tengion, Inc.
KOOL ThermoGenesis Corp.
TIG Tigenix NV
** added after original index portfolio was created October 18
Thursday, October 18, 2012
My cell therapy index portfolio
So there are certainly analysts, traders, and brokers who cover the public segment of the cell therapy industry with much more expertise and experience than I. Certainly among the top of this crop is Henry W. McCusker of Scimitar Equity (@henryw09 on Twitter) who is preparing to launch a major new online initiative that I'm very excited about covering the entire regenerative medicine sector focused primarily on the public companies in the sector.
I tend to focus more attention on the activity of private companies in the sector that tend to get a lot less spotlight but as you know I have created a portfolio of public cell therapy companies comprised of the 30 companies listed below (linked to their page on Google Finance).
I've been watching this portfolio since the beginning of the calendar year (January 2012) and have been commenting on its performance as against some of the major indices. (Oct 8 post and August 10 post).
In addition to these occasional reports I will occasionally report on Twitter (@celltherapyblog) on the stocks in this portfolio which are enjoying the largest gains/losses and which have the largest/smallest trading volumes. From time-to-time I will aggregate this content into a blog post.
Monday, October 8, 2012
Cell therapy portfolio outperforms major indices year-to-date
On August 10 we created a model portfolio in Google Finance of 29 public companies in the cell therapy sector then we compared how that portfolio was doing against the major indices year-to-date (Since 1 January 2012). See that post here. Bottom line: even though we are still in a relatively bullish market, the CT portfolio was doing better. Significantly better.
So how is the sector portfolio doing now that we've been through three quarters?
In case you can't read the image above, the blue line represents the cell therapy portfolio and here are the stats on performance since 1 January 2012:
- Cell Therapy Portfolio: +63.17%
- Dow Jones: +11.17%
- S+P 500: +15.76%
- Nasdaq: +19.46%
The only change I've made to the portfolio of 29 companies listed in our August 10 post is to add Thermogenesis (KOOL). Today its stock is at .968 up from .7 at the beginning of the year.
You do or should know, I'm no financial analyst. I'm not entirely sure what assumptions are behind this 'model portfolio' or precisely what one should take from this snapshot but what is clear to me is that at least from one perspective the sector is treating investors fairly well.
I certainly welcome comments from more sophisticated investors or analysts. In fact, if anyone with that kind of experience or expertise wants to write a guest post on this blog providing a more sophisticated commentary on what this all means, I would very much welcome the contribution.
In the meantime, I hope this helps.
_________________
Post-publication addition:
Carter Gould, Associate Biotech Analyst at Dawson James Securities emailed me to point out that the cell therapy portfolio is simply riding the bull wave of biotech in general and and the more relevant comparison index is the broader biotech (BTK) index which is up 45% YTD. Here is a YahooFinance snapshot of the BTK performance vs the three major indices.
Friday, August 10, 2012
Is the cell therapy sector outperforming the major indices?
So here's what I did today. I built a portfolio of public companies focused exclusively or predominately in the cell therapy space. I excluded any companies that are in the sector but their products/services constitute less than a significant majority of their revenue and/or expenses. The portfolio sits at 29 companies. Here's the list:
.jpg)
Here's how the portfolio performs against the Dow Jones, Standard and Poor's, and NASDAQ indices so far this year.
.jpg)
When looking at the period 1 January 2012 to 10 August 2012, the cell therapy portfolio is up 42%, Dow Jones up 8%, Standard and Poor's up 12% and NASDAQ up 16%.
In the context of how much we hear about how harsh this sector is or has been on investors, I found today's analysis interesting and, honestly, pleasantly surprising.
This snapshot is useful but has its limitations. I'm relying on Google Finance for accuracy of the information provided. Do your own due diligence. Invest accordingly. I hope this helps.
--Lee
This snapshot has been brought to you by Cell Therapy Group: all cell therapy, all the time! :)
Subscribe to:
Posts (Atom)